HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
NZ 107
structure given in first source; LTB4, LTC4 and LTD4 antagonist;
Also Known As:
4-bromo-5-(3-ethoxy-4-methoxybenzylamino)-3(2H)-pyridazinone; NZ-107; 3(2H)-Pyridazinone, 4-bromo-5-(((3-ethoxy-4-methoxyphenyl)methyl)amino)-
Networked:
7
relevant articles (
2
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridazines: 11
NZ 107: 7
Related Diseases
1.
Asthma (Bronchial Asthma)
04/01/1993 - "
These results indicate that NZ-107 prevents the increased number of pulmonary eosinophils and airway epithelial cells and the activation of macrophages and eosinophils, suggesting that NZ-107 may be useful as a remedy for airway inflammatory diseases such as bronchial asthma.
"
07/09/1991 - "
These results suggest that NZ-107 may be a useful drug for the treatment of bronchial asthma by reducing late-phase airway responses and airway hyperreactivity.
"
05/01/1991 - "
These results suggest that NZ-107 may have a unique profile for adenosine responses in bronchial asthma.
"
11/01/1989 - "
From these results, NZ-107 is a selective inhibitor of the SRS-A response and may be useful in the therapy of bronchial asthma and other diseases in which the LTs are thought to be involved.
"
01/01/1992 - "
These results indicate that NZ-107 acts as a spasmolytic agent which inhibits bronchial responses to antigens or various other bronchoconstrictors in animal models, suggesting that NZ-107 may be potentially beneficial in the treatment of bronchial asthma.
"
2.
Inflammation (Inflammations)
04/01/1993 - "
Effects of NZ-107 on airway inflammation and cell activation in guinea-pigs.
"
04/01/1993 - "
The effects of NZ-107 on some airway inflammation models and the generation of superoxide anion (O2-) were studied in guinea-pigs.
"
03/01/1997 - "
NZ-107 was studied for its effect on airway inflammation caused by intratracheal injection of LTB4 or IL-5, or by inhalation of PAF, and by cell activation.
"
3.
Hypersensitivity (Allergy)
09/01/1992 - "
The effects of 4-bromo-5-(3-ethoxy-4-methoxybenzylamino)-3(2H)-pyridazinone (NZ-107) on immediate type hypersensitivity reactions in rats and guinea-pigs were studied.
"
09/01/1992 - "
Effects of a newly synthesized leukotriene antagonist, NZ-107, on immediate-type hypersensitivity reaction in rats and guinea-pigs.
"
4.
Eosinophilia
04/01/1993 - "
NZ-107 (4-bromo-5-(3-ethoxy-4-methoxybenzylamino)-3(2H)-pyridazinone) at a dose of 50 mg kg-1, intraperitoneally reduced mrIL-5- and PAF-induced eosinophilia.
"
5.
Cough
01/01/1992 - "
NZ-107 in a high dose of 100 mg/kg per os significantly prevented aerosolized antigen-induced anaphylactic collapse, but not cough in actively or passively sensitized conscious guinea pigs and also significantly protected aerosolized histamine-induced collapse, but not cough in conscious guinea pigs.
"
01/01/1992 - "
In conscious guinea pigs, pretreated with indomethacin, pyrilamine and propranolol, passively sensitized with heterologous anti serum, NZ-107 in doses of 10-30 mg/kg per os inhibited the aerosolized antigen-induced cough and collapse.
"
Related Drugs and Biologics
1.
Bronchoconstrictor Agents
2.
Parasympatholytics (Antispasmodics)
3.
Antigens
4.
Leukotriene Antagonists (Leukotriene Receptor Antagonists)
5.
Interleukin-5 (Interleukin 5)
6.
Superoxides (Superoxide)
7.
SRS-A
8.
Pyrilamine (Mepyramine)
9.
Propranolol (Inderal)
10.
Leukotriene B4
Related Therapies and Procedures
1.
Therapeutics